- Current report filing (8-K)
April 27 2012 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): April 26,
2012
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
No. 14 East Hushan Road,
Taian City, Shandong,
271000
Peoples Republic of China
(Address of Principal
Executive Offices)
86-538 -620-2306
Registrant's telephone number,
including area code
____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS;
ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS.
Mr. Y. Tristan Kuo resigned from his position as the Companys
Chief Financial Officer and from any other positions he currently holds at the
Companys subsidiaries, effective May 31, 2012. Mr. Kuo is pursuing a new career
opportunity and will serve the Company as an independent consultant for the next
twelve months. The Companys Board of Directors (the Board) appointed Mr. Ming
Yang, the Companys Vice President-Finance & Compliance and Treasurer, as
the interim Chief Financial Officer, effective May 31, 2012.
Mr. Ming Yang joined the Company in March 2012 and has been
serving as the Companys Vice President-Finance & Compliance and Treasurer
in charge of financial management, internal controls, legal and compliance
matters, and the implementation of corporate governance rules and policies and
related decisions of the Board. There is no material change to Mr. Yangs
compensation arrangement as a result of his appointment as the interim Chief
Financial Officer.
Mr. Yang has six years of financial management experience in
corporations and eleven years of audit experience in accounting firms. Mr. Yang
has extensive experience in dealing with Chinas tax regulations, Peoples
Republic of China GAAP, IFRS, and internal control matters. He was an audit
senior manager at KPMG, where he provided audit services for initial public
offerings, rights issues, and merger and acquisition transactions. He also
worked on the annual reports of various public companies listed in Hong Kong and
mainland China. His audit clients ranged from state-owned enterprises and
Chinese listed companies to multinational companies. Among his clients were
Angang Steel, China Shenhua Energy, BOE Technology, and BHP Billiton. Before
joining the accounting firms, Mr. Yang worked as an accountant and finance
manager for several Chinese companies. Mr. Yang is a certified public accountant
in China. He is 40 years old.
There is no family relationship between Mr. Yang and any
directors or other executive officers of the Company. In addition, there has
been no transaction, nor is there any currently proposed transaction, between
Mr. Yang and the Company that would require disclosure under Item 404(a) of
Regulation S-K.
On April 27, 2012, the Company issued a news release announcing
the above-referenced change of executive officer. A copy of the news release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: April 27, 2012
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
By:
/s/ Chao Ming
Zhao
|
|
Chao Ming Zhao
|
|
Chief Executive Officer
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024